Business, energy, technology, markets and global industry news from Business News Today

Zepbound

PharmaDeviceNews Zepbound
Novellia’s GLP-1 and Metabolic Health Registry aims to track weight outcomes, treatment persistence and coverage disruptions across complex patient journeys, addressing evidence gaps left by traditional healthcare datasets. Representative image.
Pharma & Biotech

Novellia’s GLP-1 registry found a surprising weight-loss pattern, but what does it really prove?

See how Novellia’s GLP-1 registry could sharpen real-world evidence while facing tests on validation, bias, privacy and payer use.

Read More
Pharma & Biotech

Evidation GLP-1 study reveals major growth runway but exposes widening access gaps

Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.

Read More
Representative image of a clinical weight-management consultation with an injection pen and progress chart, reflecting Pfizer’s berobenatide Phase 2b data and the growing race to develop monthly GLP-1 obesity treatments.
Pharma & Biotech

Pfizer’s Phase 2b obesity data put monthly GLP-1 dosing back in investor focus

Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.

Read More
Representative image: Eli Lilly’s expanding diabetes and obesity drug pipeline, including Foundayo, Mounjaro and retatrutide, highlights the growing race to reshape cardiometabolic care through oral GLP-1 therapies, injectable incretin drugs and next-generation clinical trial advances.
Pharma & Biotech

Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?

Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.

Read More
Zepbound KwikPen arrives on Ro as Eli Lilly tightens control over obesity drug distribution
Medical Devices & Diagnostics

Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing

Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.

Read More
Representative image showing oral weight loss medication with a measuring tape and water glass in the background, illustrating the growing shift from injectable GLP-1 therapies to convenient, daily oral treatments like orforglipron.
Features & Analysis

Can oral GLP-1s maintain weight loss after injectables? Lilly’s orforglipron may prove it can

Eli Lilly and Company (Lilly) has reported positive topline results from the ATTAIN-MAINTAIN Phase 3 trial evaluating orforglipron, its once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for maintenance of weight loss in patients previously treated with injectable incretins. The trial enrolled participants who had completed 72 weeks of treatment with semaglutide (Wegovy) or tirzepatide (Zepbound)

Read More
Novo Nordisk is seeking approval for 7.2 mg Wegovy (semaglutide) from the FDA .
Pharma & Biotech

Can higher-dose Wegovy reshape the obesity treatment curve for Novo Nordisk?

Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.

Read More